A 61-year-old female with a history of hypertension, hyperlipidemia, gastroesophageal reflux disease, and arthritis requiring several orthopedic procedures presented to her primary care physician complaining of a rash on her neck. A complete metabolic panel showed that her liver function tests were elevated, and her simvastatin was discontinued. She was referred to a dermatologist and was treated with oral antibiotics and topical cream. Eventually, she presented to the emergency department (ED) following a fall resulting in a fracture of the fifth metatarsal of her left foot.
A 61-year-old female with a history of hypertension, hyperlipidemia, gastroesophageal reflux disease, and arthritis requiring several orthopedic procedures presented to her primary care physician complaining of a rash on her neck. A complete metabolic panel showed that her liver function tests were elevated, and her simvastatin was discontinued. She was referred to a dermatologist and was treated with oral antibiotics and topical cream. Eventually, she presented to the emergency department (ED) following a fall resulting in a fracture of the fifth metatarsal of her left foot.
In the ED, she stated that the rash had spread to her face, upper torso, arms, and legs over the course of 3 weeks. She also complained of increasing weakness and multiple falls accompanied by myalgias and cramping in her thighs. She had difficulty arising from a chair, lifting her arms over her head, and lifting her head off the bed. She denied difficulty manipulating objects with her hands but did endorse worsening dysphagia and odynophagia. She denied any alcohol, tobacco, or other drug use aside from her prescribed omeprazole, aspirin, and lisinopril. She denied any exotic travel or flu-like symptoms. Family history was remarkable for rheumatoid arthritis in her mother and sister.
On general examination, she was an obese caucasian female in no acute distress. Blood pressure was 128/68 mm Hg, heart rate was 96 beats/min, temperature was 36.7 C, and oxygen saturation was 97% on room air. A red maculopapular rash was noted over her knuckles, neck, chest, forearms, and thighs. Her eyelids were a purple hue and a malar rash was present. She had anicteric sclerae, pharyngeal erythema, regular cardiac rhythm, clear lungs, normal bowel sounds without distention, and a cast on her left foot placed by the ED physician. On neurologic examination, she was alert and fully oriented with a normal cognitive mental status examination. Her cranial nerves were intact, with full strength in her occuli, orbicularis oris, masseter, and temporalis muscles; she had no dysarthria. She had 4/5 strength in her neck flexors and extensors and 3/5 strength in her deltoids, biceps, and triceps bilaterally; wrist and hand power was 4/5. Hip flexor and quadriceps strength were symmetric at 2/5 and 4/5, respectively. Reflexes were normal and symmetric throughout. Sensory examination was normal aside from the painful rash. Serum laboratory analysis revealed increased creatine phosphokinase (CPK) and muscle related enzymes (Table 1) , as well as elevated inflammatory markers (erythrocyte sedimentation rate 77; C-reactive protein 3.35). Electrocardiograph (ECG) showed normal sinus rhythm. Chest X-ray was clear without consolidation or hypoventilation. Computed tomography (CT) and magnetic resonance imaging (MRI) of head and spine were normal. Modified barium swallow confirmed dysphagia with overt aspiration. The patient was admitted and subsequently transferred to Emory University Hospital for further management.
Clinical Evaluation of Proximal Weakness Discussant: James G. Greene
Clinical evaluation of all patients with weakness begins with a thorough history and examination. The history provides the nature and temporal course of the symptoms, potential hereditary risks, and anatomic distribution of the weakness. In this case, the time course was subacute and progressive, occurring over 3 weeks and worsening dramatically. Confrontational testing confirmed the proximal muscle weakness suggested by her functional difficulties (arising from a chair, lifting her arms, etc). Lastly, she complained of myalgias and cramping which are nonspecific but frequently associated with muscle disease.
Taken together, the signs and symptoms point to a symmetric proximal myopathy. The presence of dysphagia and odynophagia suggested additional involvement of the striated muscles of the oropharynx and/or esophagus that could be confirmed by modified barium swallow. The appearance of a rash in temporal proximity to weakness is suggestive of an inflammatory myopathy (IM). The 3 types of IM that present with a limb-girdle pattern of weakness and rash are dermatomyositis (DM), polymyositis (PM), and overlap syndromes.
Although DM was suspected on clinical grounds, specific diagnosis by ancillary methods was required to direct treatment and patient education concerning prognosis.
Ancillary Evaluation of Suspected IM
Electrodiagnostic studies can help to localize the disease to the muscle. In IMs, nerve conduction studies are typically normal. In contrast, electromyography can demonstrate characteristic myopathic changes, including increased insertional and spontaneous activity with fibrillation potentials, positive sharp waves, and rare pseudomyotonic or complex repetitive discharges; short duration, low amplitude, polyphasic motor unit action potentials; and early recruitment of motor units.
Imaging of the affected weak limbs may also reveal inflammatory muscle pathology and can help direct a muscle biopsy. 1 Skeletal muscle MRI with proton density fat suppression may reveal increased signal within the muscle indicating inflammation and consequent edema. However, abnormalities on MRI have not been found to be associated with degree of weakness or prognosis.
Laboratory evaluation of a suspected IM starts with a serum CPK level. Although CPK level does not correlate with the severity of weakness, it is typically elevated in patients with inflammatory muscle disease. It may be normal in slowly progressive myopathies, as well as in 20% to 30% of patients with DM. 2, 3 Other components are likely to be elevated, including aldolase, myoglobin, lactate dehydrogenase, aspartate aminotransferase, and alanine aminotransferase ( Table 1 ).
An overlap myositis is thought to occur when a presentation of inflammatory myositis is found to be associated with either a clinical overlap feature or an overlap-associated autoantibody. As such, in addition to serum markers of muscle injury, further laboratory workup to elucidate specific inflammatory markers is warranted to determine whether the disease presentation is the result of an overlap syndrome.
Muscle biopsy is a necessary confirmatory test, especially if long-term immunosuppressant treatment regimens are to be considered. Inflammatory myopathies are characterized by the presence of inflammatory cells within the connective tissue between myofibers and around blood vessels.
Evaluation of this particular patient should proceed with EMG, laboratory evaluation of serum autoantibodies, and muscle biopsy.
Diagnostic Results
Electrodiagnostics in this patient demonstrated diffuse fibrillations, myopathic potentials, and a mild axonal polyneuropathy of the lower extremities. Laboratory workup demonstrated an increased antinuclear antibody (ANA) and anti-PM-Scl autoantibody ( Table 2 ). Biopsy of the left deltoid muscle was obtained and evaluated with hemotoxylin and eosin (H&E), modified Gomori trichrome, myosin ATPase, nicotinamide adenine dinucleotide (NADH), succinate dehydrogenase (SDH), acid phosphatase, cytochrome cxidase, oil red O, and periodic acid Schiff stains. The samples were found to demonstrate primary perivascular inflammation and a diffuse necrotizing myopathy. Importantly, perifascicular atrophy was not seen (Figure 1 ).
Dermatomyositis and Overlap Syndromes Discussant: Jonathan D. Glass
Dermatomyositis is an IM that presents in childhood or adulthood characterized by a rash that accompanies, precedes, or follows the onset of muscle weakness. Diagnostic criteria proposed by Bohan and Peter are the most common criteria used for assessing DM/PM (Table 3) sclerodermatomyositis (SDM) overlap syndrome. The clinical overlap symptoms found in SDM include arthralgias and polyarthritis (35%), interstitial lung disease (60%), lower esophageal and/or small bowel hypomotility (20%), Raynaud phenomena (40%), as well as other symptoms of connective tissue disease. 6 Overall, our patient's muscle biopsy results were not characteristic of classic DM pathology but demonstrated the typical mileu associated with IM. Indeed, in SDM, more than 60% of muscle biopsies have shown heterogeneous features of muscle inflammation including mononuclear inflammatory infiltrates and necrosis in perivascular, perimysial, and or endomysial regions. 7 Less common are more specific features of systemic sclerosis such as microangiopathy or increased fibrosis in the perimysium and epimesium.
Antinuclear antibodies are discovered in 24% to 60% of DM and 16% to 40% of PM but occur with higher frequency in overlap myositis (61.5%) than pure myositis (25.4%). 8 Overlap antibodies include the antisynthetases, systemic sclerosis-associated autoantibodies, antinucleoporins, and antisignal recognition particle (SRP) antibodies. Anti-PM-Scl antibodies have been found in 5% to 25% of patients with myositis, and PM-or DM-scleroderma overlap syndromes account for approximately 43% to 88% of myositis associated with anti-PM-Scl autoantibodies. The prognostic and therapeutic features that define SDM associated with anti-PM-Scl autoantibodies are still being defined.
Dermatomyositis was first shown to be associated with malignancy in 1916 and has since been shown to convey an increased risk of cancer. A large population-based study comprising patients from Sweden, Denmark, and Finland demonstrated a 3-fold increase in risk of malignancy in DM. 9 The most likely cancers to be associated with DM were found to be ovarian, pancreatic, stomach, colorectal cancers, and lymphoma. Approximately 70% of the discovered cancers were adenocarcinoma and were detected within the first year after the diagnosis of DM, although the increased risk of malignancy remained for 5 years following diagnosis. Although there have been several other studies confirming this risk, there are no consensus guidelines for malignancy screening in DM. However, there is agreement that patients with DM are at high risk and should be screened for malignancy for several years following DM diagnosis. In patients with SDM, the association is not clear. 10, 11 Our patient was current with all of her regular screenings including normal colonoscopy, pelvic examination, and mammogram within the past year. Additional tests performed to screen for occult malignancy, including a contrasted CT of the chest, abdomen, and pelvis and serum testing for recognized markers of malignancy (CA-19-9 and CA-125) were normal.
Inclusion body myositis (IBM) often is included in the differential diagnosis of IMs. There are several reasons why IBM is unlikely in this patient. First, the time course of IBM tends to be progressive over several years with marked atrophy. Muscle weakness in patients with IBM is typically asymmetrical, affecting both proximal and distal muscles, with a tendency for weakness of the quadriceps and long finger flexors. Pathologically, IBM shows "rimmed" vacuoles that contain amyloid and stain with antibodies to ubiquitin. These pathological findings and the resistance of IBM to immunotherapy have lead many clinicians to consider IBM a degenerative disease of muscle as opposed to an acquired primary autoimmune or inflammatory disorder. As far as treatment is concerned, systemic glucocorticoids have been shown to drastically decrease mortality in IM, despite the lack of randomized control trials. 12 Oral prednisone at 1 mg/kg per d has been used in the acute phase of the disease with good results; this dose is usually continued for 4 weeks and then tapered while monitoring the CPK levels. In patients with dysphagia or severe acute disease, intravenous (IV) methylprednisolone is typically used. A small clinical trial comparing the efficacy of IV methylprednisolone plus prednisone in comparison to prednisone alone demonstrated an increased rate of complete and sustained remission in the IV methylprednisolone group. 13 The treating physician must be vigilant for worsening of muscle weakness with steroid treatment because an iatrogenic steroid myopathy may develop.
Despite the availability of various treatment modalities, the majority of patients experience flares or chronic progression of the disease. Because of this, second-line immunosuppressants such as methotrexate, azathioprine, and cyclosporine are often necessary to treat patients with steroid-resistant disease. These agents typically have a 70% positive response rate and may be prescribed from the onset of treatment with glucocorticoids. 14 Intravenous immunoglobulin (IVIG) and targeted immunotherapy have shown some efficacy in steroidresistant cases and are still being investigated. 15 Treatments for the dermatologic manifestations of IM that do not resolve with systemic treatment include sunlight protection, topical steroids, oral hydroxychloroquine, and topical tacrolimus. 14 In addition to the medical treatment of the underlying inflammatory process, patients with IM also benefit from physical therapy and exercise in order to prevent and correct the muscle destruction caused by the disease and steroid treatment. Correcting any nutritional deficits subsequent to dysphagia or odynophagia is also important to the healing process.
In this patient, a percutaneous endoscopic gastrostomy tube was necessary for nutritional supplementation due to her debilitating dysphagia. She received a short course of IV methylprednisolone followed by oral prednisone. Her rash responded rapidly to the steroids, and she was discharged to inpatient rehabilitation on prednisone and azathioprine.
